Everest Medicines Ltd. · HKEX:1952
Everest Medicines — Investor Presentation (December 2024)
30 slides from Everest Medicines's investor presentation, December 2024
Slide 1: Corporate Deck
Corporate Deck December 2024
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Everest Medicines Limited (the “Company” and together with its subsidiaries, the “Group”) solely for information purposes and does not constitute a recommendation regarding the securities of the Group or an offer to sell or issue or the solicitation
Slide 3: Fully Integrated Biopharma: Dual Engine Strategy to Value Creation
Fully Integrated Biopharma: Dual Engine Strategy to Value Creation Differentiated portfolio drives Commercial Platform commercial cash flow Leverage commercial platform to • Drive organic revenue growth • Expand pipeline in core therapeutic maximize synergies areas and increase scale and efficiency
Slide 4: Pursuing Asian Leadership Position in "Blue Ocean" Therapeutic Areas
Pursuing Asian Leadership Position in “Blue Ocean” Therapeutic Areas To be a leading biopharma in Asia Pacific by 2030, we aim to create social impact Vision through our innovative medicine portfolio and sustainable growth. 3 core therapeutic areas with 4 near term products aggregated peak sales pot
Slide 5: Broad Pipeline With Multiple First-in-class or Best-in-class Products
Broad Pipeline With Multiple First-in-class or Best-in-class Products in Our Focus Treatment Areas Everest Clinical Status NDA/BLA Molecule Global Clinical Partner Commercial Right Indication Pre- BLA/NDA Status approval (Modality) Phase1 Phase2 Phase3 Approval clinical Application Greater China, Ap
Slide 6: 1H 2024: Solid Revenue Growth with Focus on Operating Efficiency and Strong Balance Sheet
1H 2024: Solid Revenue Growth with Focus on Operating Efficiency and Strong Balance Sheet Substantial High gross Significantly Strong cash revenue growth margin1 narrowed non- balance as % of revenue IFRS net loss2 RMB 301.5M RMB 212.6M +158% vs.2H 2023 83% -35% vs.1H 2023 RMB 1.93B Achieved commerc
Slide 7: Strong Sales Growth Driven by NEFECON and XERAVA, Reiterate Full Year Revenue Guidance
Strong Sales Growth Driven by NEFECON® and XERAVA®, Reiterate Our Full Year Revenue Guidance Product revenue (RMB M) +158% Launched in May Continued revenue 301.5 2024 ramp up 167.3M 134.2M 117.0 2H 2023 1H 2024 On track for the full year revenue guidance of 700M RMB 7
Slide 8: Significant Unmet Medical Needs in IgAN Addressed by NEFECON
Significant Unmet Medical Needs in IgAN Addressed by NEFECON® Substantial unmet medical needs in China No approved therapy prior to NEFECON® Current treatment options, such as RAS inhibitors, are 5M non-targeted and used off-label IgAN Patients Current treatment options do not alter disease progress
Slide 9: Results from China Subpopulation Showed Greater NEFECON Treatment Effect
Results from China Subpopulation Showed Numerically Greater NEFECON® Treatment Effect in Kidney Function, Proteinuria and Microhematuria Compared with Global Data ✓ Chinese subpopulation in control group (RAS inhibitor) showed more rapid deterioration in eGFR and UPCR than global population Mean cha
Slide 10: Successful Commercial Launch of NEFECON in China
Successful Commercial Launch of NEFECON® in China Successful commercial launch in China by leveraging online and offline innovative approaches Online Traditional prescription hospitals Focused and highly efficient commercial organization ~150 sales representatives 500-700 hospitals >60% of market po
Slide 11: KDIGO 2024 Guideline (Public Review Draft): IgAN Treatment
KDIGO 2024 Guideline (Public Review Draft) : IgAN Treatment • The focus of management in most patients should be to simultaneously： ‒ Prevent or reduce IgA immune complex formation and immune complex-medicated glomerular injury ‒ In parallel, manage the consequences of existing IgAN-induced nephron
Slide 12: Significant Unmet Clinical Needs and Limited Therapeutic Options for MDR Infections
Significant Unmet Clinical Needs and Limited Therapeutic Options for MDR Infections Substantial unmet medical needs in China Current treatment options cannot fully meet clinical needs Low tissue concentration, High carbapenem resistance rates Tigecycline adverse events, Black Box warning (all-cause
Slide 13: XERAVA Revenue Continues to Grow by Expanding and Deepening Hospital Coverage
XERAVA® Revenue Continues to Grow by Expanding and Deepening Hospital Coverage Sales reps ~120 Target hospitals ~300 1 Medical publications 5 New guideline inclusions 3 Core market Treated patients increased by ~300% vs. 2023 2H Non-core market: Hospital listing increased by ~75% vs. 2023 2H CSO par
Slide 14: Complementary Products in Our Therapeutic Area Focus of MDR Infection Treatment
Complementary Products in Our Therapeutic Area Focus of MDR Infection Treatment (Eravacycline) Cefepime-taniborbactam EVER206 (SPR206) First-in-class fluorocycline Best-in-class BL/BLI, with potent antibiotic, broad spectrum and selective inhibitory activity A novel polymyxin derivative with coverag
Slide 15: Etrasimod: Approved in Macau and Expected to Launch in Greater Bay Area in 2H 2024
Etrasimod: Approved in Macau and Expected to Launch in Greater Bay Area in 2H 2024 19 Designated medical institutions in Guangdong approved to use clinically urgently needed drugs that have been marketed in Hong Kong and Macau Effective, oral advanced UC treatment well-suited Large medical needs in
Slide 16: Everest's Approach to Building Differentiated Future Pipeline
Everest’s Approach to Building Differentiated Future Pipeline In-licensing Discovery Focus on core therapeutic areas Clinically validated mRNA platform In our focused TAs Focus on late-stage and commercial-stage assets Therapeutic cancer vaccines Focus on commercial and clinical Focus on delivering
Slide 17: A Growing Pipeline of Assets with Global Rights
A Growing Pipeline of Assets with Global Rights mRNA platform Personalized Immune- EVER001 cancer TAA cancer modulatory In vivo CAR-T (BTKi) vaccines vaccines cancer vaccines Cancer Indication Membranous Cancer Cancer Cancer /Autoimmune Nephropathy Development Phase 1b/2a Launched IIT US IND submiss
Slide 18: Strategic Focus on Renal Diseases with Products Covering Multiple Diseases
Strategic Focus on Renal Diseases with Products Covering Multiple Diseases Primary Focal Segmental Indication IgA Nephropathy Membranous Minimal Change Lupus Nephritis Glomerulosclerosis (IgAN) Nephropathy Disease (MCD) (LN) (FSGS) (pMN) Prevalence in 4-5M ~2M 1-2M 500K-1M 400-600K China Prevalence
Slide 19: Disease Overview and Significant Unmet Medical Needs of Primary Membranous Nephropathy
Disease Overview and Significant Unmet Medical Needs of Primary Membranous Nephropathy Disease Overview Significant Unmet Medical Needs • Membranous nephropathy (MN) is among the No treatment has been approved for pMN. more common nephrotic syndromes in adults without diabetes with an idiopathic pri
Slide 20: EVER001: A Potent Covalent Reversible BTK inhibitor for Autoimmune Renal Indications
EVER001: A Potent Covalent Reversible BTK inhibitor Suitable for Autoimmune Renal Indications Compared with covalent and irreversible BTK inhibitors, EVER001 is potentially BIC with high selectivity and high potency EVER001 1 Reversible covalency 2 Excellent selectivity 3 Potent target binding 4 Pot
Slide 21: EVER001: Phase 1b/2a Clinical Proof-of-Concept Trial Ongoing
EVER001: Phase 1b/2a Clinical Proof-of-Concept Trial Ongoing Phase 1b/2a study in Chinese pMN patients with positive anti-PLA2R autoantibody ➢ 31 subjects were enrolled in the study in total Cohort 1: EVER001 100mg QD × 4w → 100mg BID x 32w Follow-up Extended Follow-up Period (N=10) Data from at lea
Slide 22: Most Subjects Experienced Immunological Complete Remission by 8-16 Weeks
Most Subjects Experienced Immunological Complete Remission by 8-16 Weeks ❑ Observed immunological complete remission (ICR) rate increased with treatment in both cohorts. As early as week 4-8, ICR was observed. ❑ In Cohort 1, 6 of 11 (54.5%) subjects experienced ICR at week 16, and as high as 90.9% (
Slide 23: Proteinuria Remission Achieved in Most Subjects Within 24~28 Weeks
Proteinuria Remission Achieved in Most Subjects Within 24~28 weeks ❑ In Cohort 1, 72.7% of subjects experienced proteinuria remission at week 28 with 1 subject (9.1%) achieved complete remission (CR); then 81.8% of subjects experienced proteinuria remission at week 36 with 2 subjects (18.2%) achieve
Slide 24: Positive Results from Ongoing Phase 1b/2a Study
Positive Results from Ongoing Phase 1b/2a Study EVER001 induced early onset and high rates of immunological and clinical responses ✓ Immunological response • In Cohort 1, as high as 90.9% (10/11) of the subjects achieved ICR at week 36 • In Cohort 2, all (7/7) of the subjects reached ICR at week 24
Slide 25: A Fully Integrated and Clinically Validated mRNA Platform
A Fully Integrated and Clinically Validated mRNA Platform Proprietary antigen Proprietary LNP CMC process Self-owned design algorithm delivery system development manufacturing facility ensures high leads to enhanced ensures robust (Jiashan, Zhejiang) expression of target T cell immunity mRNA DS/DP s
Slide 26: EVM16: A Personalized Neoantigen Cancer Vaccine
EVM16: A Personalized Neoantigen Cancer Vaccine Based on Specific Mutations of Cancer Patients Everest Proprietary Neoantigen Prediction Algorithm MHC binding strength/number Differential Epitope/peptide binding immunogenicity Pathogen seq score similarity WT/MT seq EVM16 … change distance MHC I and
Slide 27: EVM14: An Off-the-Shelf Tumor Associated Antigen (TAA) Vaccine
EVM14: An Off-the-Shelf Tumor Associated Antigen (TAA) Vaccine Advantages of TAA cancer vaccine Good tumor specificity (tumor vs. normal) More T cell epitopes and no HLA restriction Off-the-shelf, well suited for advanced disease Reduced manufacture costs (vs. PCV) Potential for multiple cancer indi
Slide 28: How in Vivo mRNA CAR-T Works and its Advantages
How in Vivo mRNA CAR-T Works and its Advantages ✓ Targeted LNPs (tLNPs) loaded with modified mRNAs encoding a CAR are decorated with antibodies targeted to T cells and when Advantages of mRNA in vivo CAR-T over autologous bound will be endocytosed and release their cargo. CAR T therapy ✓ mRNA is sub
Slide 29: 2025 Catalyst
2025 Catalyst Program Milestone Status Global IgAN treatment guideline (KDIGO) and China IgAN treatment guideline update Full approval from CDE Renal Disease Commercial launch in Taiwan and South Korea EVER001 Phase 1b/2a trial 1-year follow up data available Continue to improve the accessibility in
Slide 30: Q&A
Q&A CONTACT US: [email protected]
Everest Medicines — Investor Presentation (December 2024) on 6ix